Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

NCT07107256 is registered in ClinicalTrials.gov with Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. as lead sponsor.

NCT NCT07107256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07107256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Lead sponsor
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
September 25, 2025
Completion date
September 30, 2027
Enrollment
246 (estimated)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

chronic rhinosinusitis with nasal polyps (crswnp)